Chimeric antigen receptor and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10888581-B2
Application number	US-201715835329-A
Country	US
Kind code	B2
Filing date	Dec 7, 2017
Priority date	Feb 15, 2013
Publication date	Jan 12, 2021
Grant date	Jan 12, 2021

Abstract

The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.

First claim

What is claimed is:

1. One or more isolated nucleic acids comprising a nucleotide sequence(s) encoding a heterodimeric chimeric antigen receptor (CAR) comprising:
a first polypeptide comprising a first member of a dimerization pair, a first transmembrane domain, and an intracellular signaling domain; and
a second polypeptide comprising an antigen-binding domain that comprises a single chain antibody variable region that specifically binds to CD19 or an antigen expressed by an immune cell, a second member of the dimerization pair, and a second transmembrane domain;
wherein the first and second members of the dimerization pair are located intracellularly when the first and second peptides are expressed in a host immune cell and
wherein the first polypeptide does not comprise an antigen-binding domain and the second polypeptide does not comprise an intracellular signaling domain capable of inducing immune activation,
wherein a dimerizing agent dimerizes the first and second polypeptides to form the heterodimeric CAR when the first and second polypeptides are expressed by the host immune cell with the dimerizing agent bound between the dimerization pair members of the first and second polypeptides, and wherein activation of the immune cell by the formed heterodimeric CAR binding CD19 or said antigen is increased as compared to activation of the immune cell in the absence of the dimerizing agent.

2. The one or more isolated nucleic acids according to claim 1 , wherein the immune cell is a cell of a lymphocyte lineage.

3. The one or more isolated nucleic acids according to claim 2 , wherein the lymphocyte lineage is a B cell lineage.

4. The one or more isolated nucleic acids according to claim 1 , wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain.

5. The one or more isolated nucleic acids according to claim 1 , wherein the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM).

6. The one or more isolated nucleic acids according to claim 1 , wherein the first polypeptide, the second polypeptide or both comprise an intracellular costimulatory polypeptide.

7. The one or more isolated nucleic acids according to claim 6 , wherein the intracellular costimulatory polypeptides are selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.

8. The one or more isolated nucleic acids according to claim 1 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino acid sequence of the first costimulatory polypeptide in the first polypeptide.

9. The one or more isolated nucleic acids according to claim 1 , wherein the dimerizer agent is selected from the group consisting of: rapamycin, coumermycin, methotrexate, AP20187, abscisic acid, gibberellin and analogs thereof.

10. The one or more isolated nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP-rapamycin associated protein (FRB);
b) a Gibberellic Acid Insensitive (GAI) protein and a gibberellin receptor (GID1) protein;
c) FKBP and calcineurin catalytic subunit A (CnA);
d) an abscisic acid receptor (PYL) protein and an abscissic acid insensitive (ABI) protein; and
e) FKBP and cyclophilin.

11. The one or more isolated nucleic acids according to claim 1 , wherein the first and second members of the dimerization pair are selected from the group consisting of:
a) FK506 binding protein (FKBP) and FKBP;
b) gyrase B (GyrB) and GyrB;
c) dihydrofolate reductase (DHFR) and DHFR; and
d) DmrB and DmrB.

12. An isolated cell comprising the one or more nucleic acids according to claim 1 .

13. The isolated cell according to claim 12 , wherein the isolated cell is an isolated immune cell.

14. The isolated cell according to claim 13 , wherein the isolated immune cell is a lymphocyte or a NK cell.

15. The isolated cell according to claim 12 , wherein the cell is a human cell.

16. One or more isolated nucleic acids comprising a nucleotide sequence(s) encoding a heterodimeric chimeric antigen receptor (CAR) comprising:
a first polypeptide comprising a first member of a dimerization pair, a first transmembrane domain, and an intracellular signaling domain; and
a second polypeptide comprising an antigen-binding domain that comprises a single chain antibody variable region, a second member of the dimerization pair, and a second transmembrane domain;
wherein the first and second members of the dimerization pair are located intracellularly when the first and second peptides are expressed in a host immune cell,
wherein the single chain antibody variable region specifically binds to an antigen selected from the group consisting of: CD19, CD20, CD38, CD30, Her2/neu, ERBB2, CA125, MUC-1, prostate-specific membrane antigen (PSMA), CD44 surface adhesion molecule, mesothelin, carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), EGFRvIII, vascular endothelial growth factor receptor-2 (VEGFR2), high molecular weight-melanoma associated antigen (HMW-MAA), MAGE-A1, IL-13R-a2 and GD2; and
wherein the first polypeptide does not comprise an antigen-binding domain and the second polypeptide does not comprise an intracellular signaling domain capable of inducing immune activation, wherein a dimerizing agent dimerizes the first and second polypeptides to form the heterodimeric CAR when the first and second polypeptides are expressed by the host immune cell with the dimerizing agent bound between the dimerization pair members of the first and second polypeptides, and wherein activation of the immune cell by the formed heterodimeric CAR binding said antigen is increased as compared to activation of the immune cell in the absence of the dimerizing agent.

17. The one or more isolated nucleic acids according to claim 16 , wherein the antigen is CD19.

18. The one or more isolated nucleic acids according to claim 16 , wherein the intracellular signaling domain is a CD3-zeta intracellular signaling domain or a ZAP-70 intracellular signaling domain.

19. The one or more isolated nucleic acids to claim 16 , wherein the intracellular signaling domain comprises an immunoreceptor tyrosine-based activation motif (ITAM).

20. The one or more isolated nucleic acids according to claim 16 , wherein the first polypeptide, the second polypeptide or both comprise an intracellular costimulatory polypeptide.

21. The one or more isolated nucleic acids according to claim 20 , wherein the intracellular costimulatory polypeptide is selected from the group consisting of: 4-1BB, CD28, ICOS, OX-40, BTLA, CD27, CD30, GITR, and HVEM.

22. The one or more isolated nucleic acids according to claim 16 , wherein the first polypeptide comprises a first costimulatory polypeptide comprising an amino acid sequence and the second polypeptide comprises a second costimulatory polypeptide comprising an amino acid sequence that has at least 95% amino acid identity to the amino acid sequence of the first costimulatory polypeptide in the first polypeptide.

23. The one or more isolated nucleic acids according to claim 16 , wherein the dimerizer agent is selected from the group consist

Assignees

• Univ California

Inventors

• Wu Chia-Yung
• Onuffer James
• Lim Wendell A

Classifications

• A61K40/4255

  Mesothelin [MSLN] · CPC title

• A61K40/4211

  CD19 or B4 · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K35/17 Primary

  Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) · CPC title